The present invention relates to a compression bandage for treating wounds comprised of a linear elastic compression wrap and a sterilized polymer foam layer containing a plurality of 5 antimicrobial dyes with at least one dye being gram positive and at least one other dye being gram negative and a biofilm reduction agent and wherein said foam is secured to said linear elastic compression wrap.

The present invention relates to a compression bandage for treating wounds comprised of a linear elastic compression wrap and a sterilized polymer foam layer containing a plurality of 5 antimicrobial dyes with at least one dye being gram positive and at least one other dye being gram negative and a biofilm reduction agent and wherein said foam is secured to said linear elastic compression wrap.

A polyurethane foam wound dressing, the foam integrally comprising an oxidoreductase enzyme and a substrate for the enzyme. The foam is produced by mixing a polyurethane polymer, water, an oxidoreductase enzyme and substrate for the enzyme and drying the resulting product.

A polyurethane foam wound dressing, the foam integrally comprising an oxidoreductase enzyme and a substrate for the enzyme. The foam is produced by mixing a polyurethane polymer, water, an oxidoreductase enzyme and substrate for the enzyme and drying the resulting product.

Tissue scaffold matrices, and methods of their use, are described. The matrices comprise an enzyme that is able to convert a substrate to release hydrogen peroxide and a substrate for the enzyme. The matrices may be impregnated with cells, such as stem cells. Also described are cell cultures, and methods for proliferating and/or differentiating cells.

A fibrin sealant product having a plurality of layers that each includes a dextran support and at least one fibrin sealant agent. The at least one fibrin sealant agent is placed on the dextran support to form each of the layers. The plurality of layers is placed in a stacked configuration to form the fibrin sealant product. A plurality of crimps is dispersed over a surface of the fibrin sealant product to retain the plurality of layers in a position with respect to each other.

A fibrin sealant product having a plurality of layers that each includes a dextran support and at least one fibrin sealant agent. The at least one fibrin sealant agent is placed on the dextran support to form each of the layers. The plurality of layers is placed in a stacked configuration to form the fibrin sealant product. A plurality of crimps is dispersed over a surface of the fibrin sealant product to retain the plurality of layers in a position with respect to each other.

An improved fibrinogen-based tissue sealing patch having a degradation time of less than two weeks is disclosed. The patch comprises a polyethylene glycol-caprolactone-lactide (PEG-CL-LA) triblock copolymer film in which the PEG-CL-LA units are preferably connected by urethane linkages and into a surface of which a fibrinogen-based sealant comprising less than 8 mg/cm.sup.2 fibrinogen and less than 10 IU/cm.sup.2 thrombin has been incorporated. In preferred embodiments, the polymer film comprises PEG having a molecular weight of between 3000 and 3500 and a CL:LA:PEG ratio of 34:2:1. Methods of production and use of the patch are also disclosed.

An improved fibrinogen-based tissue sealing patch having a degradation time of less than two weeks is disclosed. The patch comprises a polyethylene glycol-caprolactone-lactide (PEG-CL-LA) triblock copolymer film in which the PEG-CL-LA units are preferably connected by urethane linkages and into a surface of which a fibrinogen-based sealant comprising less than 8 mg/cm.sup.2 fibrinogen and less than 10 IU/cm.sup.2 thrombin has been incorporated. In preferred embodiments, the polymer film comprises PEG having a molecular weight of between 3000 and 3500 and a CL:LA:PEG ratio of 34:2:1. Methods of production and use of the patch are also disclosed.

A patch for treating vascular ulcers caused by excessive enzymatic activity may include a substrate configured to span a vascular ulcer as well as a linking material that is disposed relative to the substrate and has an affinity for an enzyme involved in causing the vascular ulcer. A magnetic material may be coupled to the linking material. In some cases, the enzymes involved in causing the vascular ulcer may become coupled to the linking material and thus become coupled to the magnetic material so that that the enzymes can be removed by applying a magnetic field in the proximity of the vascular ulcer. The enzymes may include matrix metalloproteinases.